About: Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
Creator	Kim, Tae-Jung Kim, Tae Kang, Ji Kim, Dong Lee, Jong Lee, Sung Cho, Min Huh, Joo Kim, Boo Hah, Jick, Hwan Woo Go, Seong
Source	Medline; PMC
abstract	Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.
has issue date	2013-12-24(xsd:dateTime)
bibo:doi	10.4046/trd.2013.75.6.256
bibo:pmid	24416057
has license	cc-by-nc
sha1sum (hex)	bd25781927e8eb5b121981ac6081cde159606c83
schema:url	https://doi.org/10.4046/trd.2013.75.6.256
resource representing a document's title	Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
has PubMed Central identifier	PMC3884114
has PubMed identifier	24416057
schema:publication	Tuberc Respir Dis (Seoul)
resource representing a document's body	covid:bd25781927e8eb5b121981ac6081cde159606c83#body_text
is schema:about of	named entity 'CHRONIC MYELOID LEUKEMIA' named entity 'PNEUMONITIS' named entity 'PATIENT' named entity 'MEDICATION' named entity 'OCCUR' named entity 'TRANSMEMBRANE RECEPTOR' named entity 'CHRONIC MYELOID LEUKEMIA' named entity 'DESCRIBE' named entity 'CASE' named entity 'FREQUENTLY' named entity 'UNDERLYING' named entity 'SUCCESSFUL' named entity 'ADMINISTER' named entity 'CML' named entity 'FUSION' named entity 'acts' named entity 'targeted therapy' named entity 'imatinib' named entity 'Imatinib' named entity 'EXPERIENCED' named entity 'ONCOPROTEIN' named entity 'TYROSINE KINASE' named entity 'PREVIOUSLY' covid:arg/bd25781927e8eb5b121981ac6081cde159606c83 named entity 'IMATINIB' named entity 'GASTROINTESTINAL STROMAL TUMORS' named entity 'INTERSTITIAL PNEUMONITIS' named entity 'DISCONTINUE' named entity 'INHIBITING' named entity 'INDUCED' named entity 'PATIENT' named entity 'PNEUMONITIS' named entity 'RECHALLENGE' named entity 'DISEASE' named entity 'CORTICOSTEROIDS' named entity 'ADVERSE EVENT' named entity 'FOLLOW-UP' named entity 'DIFFICULT' named entity 'INFECTIOUS PNEUMONIA' named entity 'INDUCED' named entity 'SUCCESSFUL' named entity 'THERAPY' named entity 'IMATINIB MESYLATE' named entity 'BCR-ABL' named entity 'RECHALLENGE' named entity '3 MONTHS' named entity 'TARGETED THERAPY' named entity 'CASES' named entity 'ACTS' named entity 'RARE' named entity 'STANDARD TREATMENT' named entity 'RECURRENCE' named entity 'IMATINIB MESYLATE' named entity 'DUE TO' named entity 'IS A' named entity 'SPECIFIC' named entity 'IMATINIB' named entity 'inhibiting' named entity 'cases' named entity 'fusion' named entity 'Mesylate' named entity 'CML' named entity 'adverse event' named entity 'Imatinib mesylate' named entity 'Pneumonitis' named entity 'Imatinib' named entity 'Philadelphia chromosome' named entity 'eosinophils' named entity 'Histological' named entity 'imatinib'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software